Across TCGA pan-cancer cohorts, CDK8 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CDK8 data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher CDK8 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CDK8 expression acts as an unfavorable survival marker.
KIRP and UCEC are the cancer types where CDK8 Mutation most reproducibly stratifies survival.